PURPOSE: To compare the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. METHODS:Thirty subjects aged 18-37 years (mean age = 24.1 years) were randomized to one of six treatment sequences in a three-treatment, three-period crossover study (William's design). Study medication was instilled b.i.d. for 5 days before visits 2, 3, and 4. Between treatments, study medication was washed out for 9-10 days. Each subject underwent a submaximal treadmill test at visits 2 through 4, 15 min after dosing. RESULTS: After 15 min of exercise, average heart rates were 143.1 +/- 21.2, 134.5 +/- 20.0 and 145.4 +/- 20.8 bpm for the unoprostone, timolol and placebo treatments, respectively. At no timepoint was there a statistically significant difference between the unoprostone and placebo treatments (p > 0.05). Beginning with the second minute of exercise, timolol produced a greater decrease in heart rate at all timepoints from placebo than unoprostone (p < 0.05). No consistent differences in systolic or diastolic blood pressure were observed between drug treatments (p > 0.05). CONCLUSIONS: Unlike timolol, unoprostone 0.15% does not reduce exercise-induced heart rate, indicating a lack of clinical effect on systemic beta-adrenergic receptors in young and healthy subjects.
RCT Entities:
PURPOSE: To compare the cardiovascular effects of unoprostone 0.15%, timolol 0.5% and placebo in healthy adults during exercise using a treadmill test. METHODS: Thirty subjects aged 18-37 years (mean age = 24.1 years) were randomized to one of six treatment sequences in a three-treatment, three-period crossover study (William's design). Study medication was instilled b.i.d. for 5 days before visits 2, 3, and 4. Between treatments, study medication was washed out for 9-10 days. Each subject underwent a submaximal treadmill test at visits 2 through 4, 15 min after dosing. RESULTS: After 15 min of exercise, average heart rates were 143.1 +/- 21.2, 134.5 +/- 20.0 and 145.4 +/- 20.8 bpm for the unoprostone, timolol and placebo treatments, respectively. At no timepoint was there a statistically significant difference between the unoprostone and placebo treatments (p > 0.05). Beginning with the second minute of exercise, timolol produced a greater decrease in heart rate at all timepoints from placebo than unoprostone (p < 0.05). No consistent differences in systolic or diastolic blood pressure were observed between drug treatments (p > 0.05). CONCLUSIONS: Unlike timolol, unoprostone 0.15% does not reduce exercise-induced heart rate, indicating a lack of clinical effect on systemic beta-adrenergic receptors in young and healthy subjects.
Authors: Tuomo Nieminen; Hannu Uusitalo; Väinö Turjanmaa; Gunilla Bjärnhall; Hans Hedenström; Jukka Mäenpää; Auli Ropo; Pekka Heikkilä; Mika Kähönen Journal: Eur J Clin Pharmacol Date: 2005-05-24 Impact factor: 2.953
Authors: Nicole L Pratt; Emmae N Ramsay; Lisa M Kalisch Ellett; Tuan A Nguyen; Elizabeth E Roughead Journal: J Ophthalmol Date: 2015-03-22 Impact factor: 1.909